









Markets
/
Stocks
/
nasdaq-pen
/

Penumbra Inc

PEN

231.540USD

-1.830-0.78%

Close 10/30, 16:00（ET）Quotes delayed by 15 min

9.02BMarket Cap

61.09P/E TTM



Penumbra Inc

231.540

-1.830-0.78%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Penumbra Inc

Currency: USD Updated: 2025-10-30

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Penumbra Inc's Score

Industry at a Glance

Industry Ranking

39 / 210

Overall Ranking

111 / 4621

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 20 analysts

Buy

Current Rating

314.167

Target Price

+34.62%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Penumbra Inc Highlights

StrengthsRisks

Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 41.02% year-on-year.

Undervalued

The company’s latest PE is 60.68, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 36.41M shares, decreasing 6.37% quarter-over-quarter.

Held by Paul Tudor Jones

Star Investor Paul Tudor Jones holds 58.19K shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-30

The company's current financial score is 9.20, which is higher than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 339.45M, representing a year-over-year increase of 13.38%, while its net profit experienced a year-over-year increase of 175.20%.

Score

Industry at a Glance

Previous score

9.20

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.32

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.70

Key Metrics

Free cash flow

No Data

Penumbra Inc's Company Valuation

Currency: USD Updated: 2025-10-30

The company’s current valuation score is 3.84, which is lower than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is 60.68, which is 3214.52% below the recent high of 2011.41 and 8754.23% above the recent low of -5251.80.

Score

Industry at a Glance

Previous score

3.84

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 39/210

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-30

The company’s current earnings forecast score is 8.30, which is higher than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Penumbra Inc is 320.00, with a high of 350.00 and a low of 266.00.

Score

Industry at a Glance

Previous score

8.30

Change

Support & Resistance

No Data

Analyst Rating

Based on 20 analysts

Buy

Current Rating

314.167

Target Price

+34.62%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

110

Total

Median

Average

Company name

Ratings

Analysts

Penumbra Inc

PEN

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Zimmer Biomet Holdings Inc

ZBH

Dexcom Inc

DXCM

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-30

The company’s current price momentum score is 6.52, which is lower than the Healthcare Equipment & Supplies industry's average of 6.55. Sideways: Currently, the stock price is trading between the resistance level at 255.13 and the support level at 218.34, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.61

Change

-0.09

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(5)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-4.112

Sell

RSI(14)

29.560

Sell

STOCH(KDJ)(9,3,3)

15.048

Sell

ATR(14)

8.201

Low Volatility

CCI(14)

-178.426

Sell

Williams %R

92.335

Oversold

TRIX(12,20)

-0.230

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

240.278

Sell

MA10

245.255

Sell

MA20

250.432

Sell

MA50

258.564

Sell

MA100

252.343

Sell

MA200

263.903

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-30

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.43. The latest institutional shareholding proportion is 93.36%, representing a quarter-over-quarter decrease of 2.47%. The largest institutional shareholder is The Vanguard, holding a total of 3.85M shares, representing 9.88% of shares outstanding, with 4.09% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

5.04M

+1.90%

The Vanguard Group, Inc.

Star Investors

3.85M

+5.05%

BlackRock Institutional Trust Company, N.A.

3.61M

+2.23%

T. Rowe Price Associates, Inc.

Star Investors

1.34M

+13.99%

State Street Investment Management (US)

1.17M

-2.25%

Elsesser (Adam)

1.02M

+1.21%

Baillie Gifford & Co.

Star Investors

922.13K

+33.84%

RTW Investments L.P.

863.55K

+0.09%

Fidelity Institutional Asset Management

818.24K

-8.57%

Champlain Investment Partners, LLC

743.71K

-14.51%

Risk Assessment

Currency: USD Updated: 2025-10-30

The company’s current risk assessment score is 7.67, which is higher than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 0.52. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.